ClinicalTrials.gg
RecruitingNCT07642882MultiStimFMUpdated Jun 11, 2026

Analgesic Efficacy of Multisite rTMS in Fibromyalgia Patients

An interventional study of rTMS and Sham in Fibromyalgia, Depression - Major Depressive Disorder and Chronic Pain, sponsored by Hospital Ambroise Paré Paris. Recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Hospital Ambroise Paré Paris · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 49 studies in Fibromyalgia with a site in France — 4 open to participants now, 5 under way, none of them phase 3. Fibromyalgia · France.

Planned enrollment
41st of 46
36 · median 80
Started
2026
the only one that year
No phase
31 of 49
3 open now
Registered
48th of 49
by date
Lead sponsor
2 of 49
Hospital Ambroise Paré Paris

Among the 49 studies in Fibromyalgia with a site in France, this one is the 41st largest by planned enrollment of the 46 interventional ones that give a count, is the only one that started in 2026, is one of 31 with no phase, and was the 48th registered.

Fibromyalgia

1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

4 of the 49 studies in Fibromyalgia with a site in France are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Fibromyalgia with a site in France, or all of them as a file.
02

Study summary

Repetitive Transcranial Magnetic Stimulation (rTMS) of the motor cortex is a recognized analgesic technique for the treatment of fibromyalgia pain, which represents a largely unmet medical need. However, the effectiveness of motor cortex rTMS is inconsistent, being observed in only about 40% of patients and not always long-lasting. It has been previously shown that predictive factors for a lack of response to motor cortex rTMS include the presence of depressive symptoms, and that prefrontal cortex rTMS is not effective for pain, even though this treatment has proven efficacy in major depressive disorder.

The hypothesis is that targeting both the motor and prefrontal cortices with rTMS will yield a particularly beneficial effect in fibromyalgia patients presenting with comorbid depressive symptoms.

Given the absence of established biomarkers for predicting rTMS response, an additional aim will be to develop reliable indicators of rTMS efficacy, based on clinical phenotype and measurements of oscillatory patterns assessed by electroencephalogram (EEG) recordings.

Read the detailed description

This is a monocentric, randomized, double-blind, parallel-group, sham-controlled trial. After providing informed consent, patients will first undergo brain magnetic resonance imaging (MRI) to determine the exact position of the coil for rTMS neuronavigation.

Clinical and psychological outcomes - assessed using validated self-report questionnaires - as well as neurophysiological parameters - including resting-state brain oscillatory activity (EEG) and cortical excitability measures (TMS and electromyography) - will be recorded at three time points: (i) at inclusion, approximately one week before treatment initiation; (ii) after completion of the 5-day intensive stimulation phase; and (iii) at the follow-up visit, two weeks after the end of treatment.

Correlations between the analgesic effects of active or sham rTMS and changes in clinical and electrophysiological parameters will be evaluated.

The treatment consists of 5 daily sessions of high-frequency rTMS of the motor and prefrontal cortex (one 30-minute session per day delivering 3000 pulses). This will be followed by: one session per week for the following 3 weeks; one session every 15 days during the following month.

This results in a total of 10 sessions over approximately 2 months.

03

Conditions studied

  • Fibromyalgia
  • Depression - Major Depressive Disorder
  • Chronic Pain

Keywords

  • Fibromyalgia
  • Chronic Pain
  • rTMS
  • Depression
  • Neuromodulation
  • EEG
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic pain lasting at least 6 months, with or without associated depressive symptoms;
  • Fibromyalgia (2016 revised ACR criteria and a FIRST questionnaire score of at least 5 out of 6);
  • Average pain intensity ≥ 4/10 on a 0-10 numeric rating scale;
  • Pain present daily or almost daily (≥ 4 days per week);
  • Patients aged over 18 and under 80 years;
  • Patients who have provided written ;
  • Patients whose analgesic treatment has been stable for at least 1 month prior to inclusion and will not need to be modified during the study;
  • Patients who can be followed for the duration of the study (10 weeks);
  • Patients covered by a health insurance plan or otherwise eligible.

Exclusion criteria

Exclusion Criteria:

  • Ongoing litigation;
  • to rTMS:
  • Implanted electronic devices and/or conductive objects near the coil: Patients with an active implanted device that is activated or controlled by physiological signals (e.g., pacemakers, implantable cardiac defibrillators [ICD], vagus nerve stimulators [VNS], wearable cardioverter defibrillators [WCD], ocular implants, deep brain stimulation systems, drug infusion pumps or ports, intracardiac leads), even if the device has been removed.
  • Non-removable metallic objects near the coil:** Patients with a conductive, ferromagnetic, or magnetically sensitive metal implant in the head or within 30 cm of the coil (e.g., cochlear implants, implanted electrodes/stimulators, aneurysm clips or coils, stents, or bullet fragments);
  • Current abuse of drugs or psychoactive substances, including alcohol (according to criteria);
  • Pregnancy or breastfeeding;
  • Epilepsy or a history of epilepsy;
  • Unstable or progressive medical conditions (e.g., cancer);
  • Psychosis according to DSM-5 criteria;
  • Presence of another pain condition more severe than the one qualifying for inclusion;
  • Failure to correctly complete pain self-assessment diaries between inclusion and randomization (fewer than 4 pain scores recorded over 7 days);
  • Inability to understand the form, or subjects under legal guardianship or curatorship;
  • Participation in another research protocol within 30 days prior to inclusion.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Active rTMS of motor and prefrontal cortex

    Each rTMS session for each cortical target will include 30 trains of pulses delivered at 10 Hz for 10 seconds (100 pulses per train), with a 20-second interval between each train, resulting in a total of 3,000 pulses per session. The total duration will be 15 to 20 minutes per target, and 30 to 40 minutes for both cortical targets combined. The stimulation intensity for the left motor cortex will be set at 80% of the resting motor threshold, defined as the minimal stimulation intensity that induces an electromyographic response of ≥50 µV in the first dorsal interosseous muscle of the hand, contralateral to the stimulated hemisphere, in at least 5 out of 10 trials. For stimulation of the left prefrontal cortex, we will use a stimulation intensity of 120% of the motor threshold, as is customary in psychiatry and as in our previous studies on analgesia (Attal et al., 2021).

    Device: rTMS

  • Sham comparator
    Sham rTMS of motor and prefrontal cortex

    To perform the rTMS, a figure-of-eight Cool-B65 A/P coil (MagVenture) will be used. This coil features a symmetrical design with two indistinguishable faces-one for active stimulation and the other for sham stimulation. The side used for each rTMS session will be determined by a personalized USB key for each patient, which will be connected to the rTMS device. The sound emitted during stimulation will be identical regardless of the side of the coil used. Finally, to further strengthen the treatment blinding for both the patient and the operator, the scalp-tapping sensation induced by active rTMS will be mimicked by low-intensity electrical stimulation applied to the head via surface electrodes. This electrical stimulation will be synchronized with the magnetic pulses during both active and sham stimulation sessions.

    Device: Sham

Interventions

  • DevicerTMS

    The active protocol will include 5 daily stimulation sessions during the first week (D1-D5), followed by one session per week for 3 weeks (W2, W3, W4), then 2 sessions spaced 2 weeks apart (W6, W8), for a total of 10 stimulation sessions. Evaluation will continue until 2 weeks after the final stimulation, that is, at week 10 after the start of treatment.

  • DeviceSham

    The sham protocol will follow an identical session schedule. Participants will be randomized to either the active or sham group in a parallel-group design, meaning each participant will receive only one of the two treatments throughout the entire duration of the study.

06

What researchers measure

Primary outcomes

  1. Change in average pain intensity over 10 weeks (Brief Pain Inventory)

    The primary outcome measure will be the mean change from baseline over the course of 10 weeks (group x time interaction) in average pain intensity from the Brief Pain Inventory (scored on a 0-10 NRS with 0 = no pain and 10 = maximal pain intensity). Baseline average pain intensity will be assessed at inclusion, and just before the first rTMS session (Day 1) and will correspond to the average of these two values. Pain intensity will be further assessed immediately before each rTMS session at Days 2, 3, 4, 5 then at weeks 2, 3, 4, 6, 8, and finally 2 weeks after the last rTMS session at week 10.

    Time frame: From enrollment to Week 10.

Secondary outcomes

  1. Weekly pain, fatigue and sleep disturbances

    Weekly average of daily patient-reported scores for pain intensity, fatigue, and sleep disturbance, recorded in a self-assessment diary completed throughout the study. Pain intensity and fatigue are each assessed on a numerical rating scale from 0 (no pain/no fatigue) to 10 (worst imaginable pain/worst imaginable fatigue), where higher scores indicate worse outcome. Sleep disturbance is assessed on a numerical rating scale from 0 (no interference) to 10 (completely disrupted sleep), where higher scores indicate worse outcome.

    Time frame: At each visit from baseline to Week 10.

  2. Immediate effect of rTMS on pain intensity

    Pain intensity at the present moment assessed immediately after each rTMS session using a Numerical Rating Scale (NRS) ranging from 0 (no pain) to 10 (worst imaginable pain).

    Time frame: At each visit from baseline to Week 10.

  3. Onset of the therapeutic effect

    The time to onset of the therapeutic effect from the first stimulation, assessed by measuring 24-hour pain scores recorded in the patient's self-assessment diary.

    Time frame: At each visit from baseline to Week 10.

  4. Brief Pain Inventory (BPI)

    The validated French version of the BPI (Cleeland and Ryan, 1994) will be used to assess maximum and minimum pain over the past 24 hours and at the present moment, as well as the impact of pain (general activity, mood, ability to walk, usual work, relationships with others, sleep, quality of life), on numerical scales from 0 to 10.

    Time frame: From enrollment to Week 10.

  5. Fibromyalgia Impact Questionnaire (FIQ)

    A validated self-report questionnaire specifically designed to assess the impact of fibromyalgia on quality of life. Scores range from 0 to 100, where higher scores indicate greater impact of fibromyalgia on functioning and worse outcome.

    Time frame: At baseline, after 5 days of treatment, at weeks 4, 6, 8 and 10.

  6. EuroQol 5-Dimension health status questionnaire (EQ-5D-5L)

    A self-report questionnaire assessing health-related quality of life across 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each rated on a 5-level scale from 1 (no problems) to 5 (extreme problems), where higher scores indicate worse outcome. A Visual Analogue Scale (EQ-VAS) ranging from 0 (worst imaginable health) to 100 (best imaginable health) is also included, where higher scores indicate better outcome.

    Time frame: At baseline, after 5 days of treatment, at weeks 4, 6, 8 and 10.

  7. Hospital Anxiety and Depression Scale (HADS)

    A self-report questionnaire assessing the severity of anxiety and depressive symptoms over the past week. It consists of two 7-item subscales - one for anxiety (HADS-A) and one for depression (HADS-D) - each scored from 0 to 21, where higher scores indicate greater symptom severity.

    Time frame: At baseline, after 5 days of treatment, at weeks 4, 6, 8 and 10.

  8. Patient Health Questionnaire (PHQ-9)

    A validated 9-item self-report questionnaire assessing the presence and severity of depressive symptoms over the past two weeks. Total scores range from 0 to 27, where higher scores indicate greater severity of depressive symptoms.

    Time frame: At baseline, after 5 days of treatment, and at Week 10.

  9. Pain Catastrophizing Scale (PCS)

    A 13-item self-report questionnaire assessing the tendency to magnify, ruminate, and feel helpless in response to pain. Each item is scored from 0 (not at all) to 4 (all the time), with a total score ranging from 0 to 52, where higher scores indicate greater catastrophizing.

    Time frame: At baseline, after 5 days of treatment, at weeks 4, 6, 8 and 10.

  10. Medical Outcome Study Sleep Scale (MOS)

    A 12-item self-report questionnaire assessing the main dimensions of sleep quality, commonly used in chronic pain syndromes. Each item is rated on a 6-point categorical scale from 1 (all the time) to 6 (never). Scores are converted to a Sleep Problems Index ranging from 0 to 100, where higher scores indicate greater sleep disturbance.

    Time frame: At baseline, after 5 days of treatment, at weeks 4, 6, 8 and 10.

  11. Short-Form McGill Pain Questionnaire (SF-MPQ)

    A 15-item self-report questionnaire assessing the sensory and affective dimensions of pain. Eleven items evaluate the sensory dimension and 4 items evaluate the affective dimension, each rated on a scale from 0 (none) to 3 (severe). Total scores range from 0 to 45, where higher scores indicate greater pain intensity.

    Time frame: At the inclusion visit, baseline, after 5 days of treatment, at weeks 4, 6, 8 and 10.

  12. Blinding Assessment Questionnaire

    A validated questionnaire administered at the end of the study to assess the integrity of blinding. Participants are asked which treatment they believe they received (active, sham, or unsure) and the reasons for their belief (side effects, symptom relief, or other).

    Time frame: At Week 10.

  13. Patient and examiner's global clinical impression (PGIC, CGIC)

    Single-item scales assessing the patient's and clinician's overall impression of change since the beginning of treatment, respectively. Both are rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), where higher scores indicate worse outcome.

    Time frame: From Week 2 to Week 10.

  14. Credibility/expectancy questionnaire (CEQ)

    A validated self-report questionnaire administered prior to treatment initiation to assess patients' beliefs about the credibility of the assigned treatment and their expectations regarding its therapeutic outcome. The first four items (Set 1), evaluating the cognitive dimensions of credibility and expectancy, will be used. Items are rated on a scale from 1 to 9, where higher scores indicate greater treatment credibility and expectancy.

    Time frame: At baseline and after the first week of treatment.

  15. Treatment responders

    The percentage of treatment responders (patients whose pain is reduced by at least 30% and 50%) at the end of treatment.

    Time frame: At Week 10.

  16. Incidence of Treatment-Emergent Adverse Events

    The safety and tolerability of the treatment, assessed by asking patients about any side effects experienced during the rTMS sessions.

    Time frame: At each visit from baseline to Week 10.

Other outcomes

  1. Predictive value of baseline clinical variables on treatment response to active rTMS and sham

    Assess the correlation between baseline clinical variables - including pain characteristics, demographic factors, and psychosocial factors - and treatment response to active rTMS and sham stimulation.

    Time frame: From enrollment to Week 10.

  2. Predictive value of baseline intracortical excitability and inhibition parameters assessed with TMS on treatment response to active rTMS and sham

    Identify the correlation between motor cortical excitability and inhibition - assessed via motor evoked potentials (recorded from the first dorsal interosseous muscle of the hand) elicited by paired-pulse TMS - and treatment response to active rTMS and sham stimulation.

    Time frame: From enrollment to Week 10.

  3. Predictive value of baseline cortical oscillatory EEG biomarkers on treatment response to active rTMS and sham

    Identify the correlation between baseline cortical oscillatory patterns extracted from resting-state EEG recordings and treatment response to active rTMS and sham stimulation. EEG recordings will consist of a 5-minute eyes-open and a 5-minute eyes-closed session using a 32-channel cap.

    Time frame: From enrollment to Week 10.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Attal N, Poindessous-Jazat F, De Chauvigny E, Quesada C, Mhalla A, Ayache SS, Fermanian C, Nizard J, Peyron R, Lefaucheur JP, Bouhassira D. Repetitive transcranial magnetic stimulation for neuropathic pain: a randomized multicentre sham-controlled trial. Brain. 2021 Dec 16;144(11):3328-3339. doi: 10.1093/brain/awab208. PubMed 34196698 ↗
  • Lapa JDDS, da Silva VA, Ciampi de Andrade D. Repetitive transcranial magnetic stimulation for fibromyalgia: are we there yet? Pain Rep. 2025 Jan 13;10(1):e1221. doi: 10.1097/PR9.0000000000001221. eCollection 2025 Feb. PubMed 39816903 ↗
  • Ciampi de Andrade D, Valiengo L. Differential Effects of Repetitive Transcranial Magnetic Stimulation on Mood and Pain Symptoms in People With Chronic Pain and Major Depressive Disorders-A Review. Eur J Pain. 2025 Aug;29(7):e70077. doi: 10.1002/ejp.70077. PubMed 40693547 ↗
  • Silva VA, Baptista AF, Fonseca AS, Carneiro AM, Brunoni AR, Carrilho PEM, Lins CC, Kubota GT, Fernandes AMBL, Lapa JDS, Dos Santos LM, Sasso I, Monte-Silva K, Poindessous-Jazat F, Mori N, Miki K, Baltar A, Tanaka C, Teixeira MJ, Hosomi K, Bouhassira D, Attal N, Ciampi de Andrade D. Motor cortex repetitive transcranial magnetic stimulation in fibromyalgia: a multicentre randomised controlled trial. Br J Anaesth. 2025 Jun;134(6):1756-1764. doi: 10.1016/j.bja.2024.12.045. Epub 2025 Mar 13. PubMed 40087077 ↗
  • Passard A, Attal N, Benadhira R, Brasseur L, Saba G, Sichere P, Perrot S, Januel D, Bouhassira D. Effects of unilateral repetitive transcranial magnetic stimulation of the motor cortex on chronic widespread pain in fibromyalgia. Brain. 2007 Oct;130(Pt 10):2661-70. doi: 10.1093/brain/awm189. Epub 2007 Sep 14. PubMed 17872930 ↗
  • Mhalla A, Baudic S, de Andrade DC, Gautron M, Perrot S, Teixeira MJ, Attal N, Bouhassira D. Long-term maintenance of the analgesic effects of transcranial magnetic stimulation in fibromyalgia. Pain. 2011 Jul;152(7):1478-1485. doi: 10.1016/j.pain.2011.01.034. Epub 2011 Mar 11. PubMed 21397400 ↗

Individual participant data

Plan to share: Undecided — The plan to share individual participant data has not yet been determined.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Nov 2028, 26 months later.

Of 439 non-industry interventional studies with no phase under Fibromyalgia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's planned 26 months is above that.

Counting every sponsor, half of 452 studies reached it within 15 months; a quarter within 6 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2026
First posted
Jun 11, 2026
StartEst.
Sep 2026
Primary completionEst.
Nov 2028
CompletionEst.
Nov 2028
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07642882
Lead sponsor
Hospital Ambroise Paré Paris
Responsible party
Nadine ATTAL (Coordinator, Hospital Ambroise Paré Paris) — Principal investigator
First posted
Jun 11, 2026
Start date
Sep 2026 (estimated)
Primary completion
Nov 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Jun 11, 2026

Study contacts

Nadine ATTAL
Contact
nadine.attal@aphp.fr
+33 1 49 09 59 31
Elisa UMMARINO
Contact
elisa.ummarino@inserm.fr
+33 1 49 09 45 56

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion